Melior Discovery about us

Melior Discovery applies its unique theraTRACE® indications discovery platform of multiplexed in vivo models to identify new therapeutic indications for development-stage pharmaceuticals. The theraTRACE® platform combines nearly 35 in vivo models in a way that allows scientists to test a molecule for its potential efficacy across a broad array of therapeutic areas.

Many blockbuster drugs were only serendipitously discovered to be efficacious in the indications where they were ultimately marketed. For example, Viagra® ($2 billion per year), Gemzar® ($1.2 billion per year), Evista® ($1.0 billion per year) and Propecia® are all examples of drugs that were originally developed for one therapy but, by chance, were discovered to be effective for a very different condition.

Melior's theraTRACE® indications discovery platform allows for a more systematic evaluation of potential novel indications. In this platform, known drug-like compounds, are comprehensively screened using a battery of in vivo tests spanning multiple therapeutic areas in order to identify potential new indications. The in vivo models that Melior uses are the same models typically used by pharmaceutical companies to determine whether a candidate is suitable for clinical testing.